Emphysema and chronic bronchitis are distinct diseases that both cause chronic obstructive pulmonary disease (COPD). Emphysema destroys alveolar walls and permanently enlarges airspaces, reducing the lung's elastic recoil. Chronic bronchitis inflames the large airways and thickens their walls, causing a productive cough for at least three months in two consecutive years. Most people with COPD have features of both, which is why clinicians treat them as one spectrum rather than two separate conditions.
Two different lesions, two different failures
The two diseases damage different parts of the lung, and that difference explains why they fail differently. Emphysema attacks the alveoli, the tiny air sacs where oxygen crosses into the blood. Chronic bronchitis attacks the bronchi, the conducting pipes that carry air to those sacs.
Emphysema begins with the destruction of elastin, the protein that lets alveolar walls stretch and snap back. Proteases, enzymes released by neutrophils and macrophages, chew through this scaffolding faster than the body can rebuild it. The result is fewer, larger airspaces instead of millions of small ones. This matters because gas exchange depends on surface area. A healthy adult lung holds roughly 300 million alveoli with a combined surface area near 70 square meters, about half a tennis court. Destruction of walls merges these sacs and eliminates their shared surfaces.
Loss of elastic recoil creates a second problem: airway collapse. Small airways stay open partly because surrounding lung tissue pulls outward on them. When that tethering tissue is destroyed, airways pinch shut during exhalation. Air becomes trapped, and the chest overinflates. This is why emphysema produces breathlessness more than cough.
Chronic bronchitis starts in the large airways. Chronic irritation triggers goblet cells to enlarge and multiply, and mucus glands to hypertrophy. The airway lining thickens, cilia lose their ability to sweep mucus upward, and secretions pool. Airway resistance rises and gas exchange becomes uneven. This is why chronic bronchitis produces daily sputum and repeated infections, and breathlessness tends to arrive later.
Inflate a balloon inside a cage, then cut some of the cage's springs. The balloon still holds air, but nothing pulls it open. That is emphysema in one image.
How much each disease contributes to COPD
Numbers make the distinction concrete. COPD affects roughly 16 million diagnosed Americans, and the CDC estimates millions more remain undiagnosed. About 75 percent of COPD cases in the United States are linked to cigarette smoking. Among people with COPD, a substantial majority have both emphysema and chronic bronchitis features on imaging or symptom review, so pure forms are the exception.
Emphysema's toll is measured in lung function. A forced expiratory volume in one second (FEV1) below 80 percent of predicted, with an FEV1-to-forced vital capacity ratio under 70 percent, defines airflow obstruction. Emphysema severity on CT is graded by the percentage of lung below -950 Hounsfield units, a density threshold; severe disease typically shows more than 20 percent low-attenuation lung. Chronic bronchitis follows a clinical definition instead: a productive cough for at least three months per year for two consecutive years.
The overlap is the rule. Population studies such as COPDGene found that most smokers with obstruction have emphysema on CT, and roughly a third report chronic bronchitis symptoms. Neither lesion fully explains the other's symptoms, and each predicts different outcomes. Emphysema extent predicts mortality and lung-function decline better than chronic bronchitis symptoms do.
In 2023, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) revises its assessment framework periodically; the enduring principle is that spirometry confirms obstruction, while symptoms and exacerbation history guide therapy. That framework treats COPD as one disease with treatable traits, not two bracketed diagnoses. The 2023 revision also promoted the term "preserved ratio impaired spirometry" for people with symptoms but a normal ratio, acknowledging that obstruction is not the only pathway to disability.
Where the distinction bends
Real patients rarely fit either textbook description. Several edge cases matter.
Women and emphysema. Women appear more susceptible to emphysema from the same tobacco exposure, with earlier and more severe disease at lower pack-years. The mechanism is debated, but airway size differences and hormonal influences are leading candidates.
Alpha-1 antitrypsin deficiency. A genetic cause of emphysema in people who never smoked, affecting roughly 1 in 3,000 to 5,000 people of European ancestry. It produces lower-lobe-predominant emphysema in young adults, typically before age 45. This is the one emphysema population where a specific therapy exists, and testing is recommended for early-onset disease, family history, or minimal smoking history.
Air pollution and biomass smoke. In low- and middle-income countries, household biomass smoke from cooking fires drives COPD in women who never smoked. The resulting phenotype often leans toward chronic bronchitis with airway-predominant disease.
Eosinophilic COPD. A subset of patients show elevated blood eosinophils and respond to inhaled corticosteroids. This trait cuts across the emphysema–bronchitis divide and illustrates why modern COPD care targets traits rather than classic labels.
The professional caveat: chronic bronchitis is defined by symptoms, not pathology. A patient can have mucus gland hyperplasia on biopsy and never meet the clinical definition, or meet the definition from another cause such as bronchiectasis. Symptom-based labels can mislead when the underlying disease is something else.
Why the old labels still confuse people
A persistent misconception holds that "pink puffer" describes emphysema and "blue bloater" describes chronic bronchitis. These terms came from mid-20th-century clinical observation and are now considered unreliable. Many patients with severe emphysema retain normal oxygen levels, and many with chronic bronchitis never develop the classic cyanosis and edema. The labels oversimplify and can delay the correct diagnosis.
A second misconception: that the two are separate diseases with separate treatments. There is no drug that reverses emphysema, and no drug that cures chronic bronchitis. Both are managed with the same core toolkit: smoking cessation, bronchodilators, pulmonary rehabilitation, and vaccination.
A third: that daily cough is harmless if you smoke. A productive cough lasting months is a red flag, not a smoker's badge. The earlier the diagnosis, the more lung function is preserved.
A counterintuitive detail: emphysema can remain silent for decades. Because the lung has enormous reserve, symptoms often appear only after 50 to 70 percent of function is lost. CT screening in eligible smokers can detect emphysema before spirometry turns abnormal, which is one reason the U.S. Preventive Services Task Force recommends annual low-dose CT for adults aged 50 to 80 with at least a 20 pack-year history who currently smoke or quit within 15 years.
Practical thresholds that trigger action
These steps are concrete and evidence-aligned.
Seek spirometry if you have a chronic cough with sputum for three months in two consecutive years, or breathlessness on stairs that was not there a year ago. Ask about alpha-1 antitrypsin testing if COPD appears before age 45, in a nonsmoker, or with a family history. A simple blood test measures the level. Get vaccinated against influenza annually, and discuss pneumococcal and COVID-19 vaccination with a clinician. Respiratory infections accelerate both diseases. Enroll in pulmonary rehabilitation if breathlessness limits daily activity. Programs typically run 6 to 12 weeks and improve exercise capacity. Stop smoking entirely, not partially. Cessation slows decline in both conditions and is the single most effective intervention. Track exacerbations: two or more per year, or one requiring hospitalization, is a threshold that changes treatment intensity.
What the science cannot yet tell you
The boundaries of this comparison are real. No biomarker reliably separates emphysema from chronic bronchitis in a living patient. CT quantifies emphysema, but chronic bronchitis has no imaging signature, only a symptom history.
Disease-modifying therapy remains elusive. Emphysema destruction is irreversible, and no approved drug rebuilds alveolar walls. Alpha-1 augmentation therapy slows decline in deficiency-related disease but does not reverse damage. Lung volume reduction procedures and transplantation help selected patients but do not address the underlying process.
The epidemiology is also incomplete. Most COPD statistics come from high-income countries with spirometry access. Global estimates rely on modeling, and underdiagnosis is the norm. What can be concluded with confidence is that the two diseases differ in mechanism, produce different symptom burdens, overlap in most patients, and share the same preventive foundation.